Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

258.66
-6.0800-2.30%
Post-market: 259.250.5900+0.23%19:59 EDT
Volume:8.29M
Turnover:2.16B
Market Cap:623.19B
PE:29.95
High:263.98
Open:263.68
Low:258.33
Close:264.74
52wk High:281.07
52wk Low:182.94
Shares:2.41B
Float Shares:2.40B
Volume Ratio:1.40
T/O Rate:0.34%
Dividend:5.24
Dividend Rate:2.03%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.33
PE(LYR):23.44

Loading ...

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
3 hours ago

Coty Names Kara Langan General Manager, U.S. Consumer Beauty Division

Reuters
·
Yesterday

Johnson & Johnson (JNJ) Stock Could Be Undervalued On Future Cash Flow

Simply Wall St.
·
Yesterday

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Yesterday

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Yesterday

Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia

Reuters
·
Sep 30

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Sep 30

Johnson: AI Providers Committed to Building Trust

THOMSON REUTERS
·
Sep 30

Johnson: We Can Keep Edge in a Safe Way

THOMSON REUTERS
·
Sep 30

Johnson: We'LL Continue to Assess and Deliberate in Coming Days

THOMSON REUTERS
·
Sep 30

Johnson & Johnson's Icotyde Seen Reaching $4.5 Billion in Peak Psoriasis Sales, BofA Says

MT Newswires Live
·
Sep 30

Update: BofA Securities Raises Price Target on Johnson & Johnson to $278 From $263, Keeps Neutral Rating

MT Newswires Live
·
Sep 29

Johnson & Johnson is Maintained at Neutral by JP Morgan

Dow Jones
·
Sep 29

J&J : Bofa Global Research Raises Price Objective to $278 from $263

THOMSON REUTERS
·
Sep 29

J&J Says Imaavy Shows Sustained Disease Control Through Two Years in Adolescent Myasthenia Gravis Study

Reuters
·
Sep 29

J&J - no New Safety Signals Identified Through Two Years of Imaavy Treatment

THOMSON REUTERS
·
Sep 29

J&J - Presents New Data on Imaavy in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

J&J - Two-Year Phase 2/3 Data Shows Sustained Disease Control and Reduced Corticosteroid Use in Adolescents

THOMSON REUTERS
·
Sep 29

Johnson & Johnson price target raised to $278 from $263 at BofA

TIPRANKS
·
Sep 29

JPMorgan Adjusts Price Target on Johnson & Johnson to $285 From $270, Keeps Neutral Rating

MT Newswires Live
·
Sep 29